BioMark Diagnostics ROA

Mitä BioMark Diagnostics tekee? BioMark Diagnostics Inc is a company based in Richmond, British Columbia, Canada. It focuses on developing and commercializing cancer diagnostic solutions for detecting, monitoring, and assessing treatment for cancer. The company went public through an IPO on November 3, 2014. BioMark Diagnostics is developing a molecular diagnostics technology platform that uses metabolomics and machine learning algorithms. This platform aims to bring new cancer diagnostics to market and improve cancer prognosis by enabling the detection of carcinomas in pre-symptomatic stages. The technology also supports measuring treatment response and serial monitoring of cancer survivors. The company's diagnostics platform leverages Omics and machine learning, with a focus on cancers that are difficult to detect and treat. A key component of its technology is a liquid biopsy assay that detects Spermidine/spermine N-acetyltransferase 1 (SSAT1), an enzyme with elevated levels in various cancers. Additionally, BioMark Diagnostics has developed a high-powered liquid biopsy metabolic panel assay designed for early-stage lung cancer diagnosis. Clinical detection capabilities of this metabolic panel have been demonstrated, though specific details are not provided. The company's website is https://www.biomarkdiagnostics.com/ and it operates under the ticker symbol BUX.CN with ISIN CA09073K1084. Its sector and industry classifications are listed as N/A on the provided data. The company is headquartered in Richmond, British Columbia, Canada. BioMark Diagnostics on yksi Eurpooliin suosituimmista yhtiöistä.